Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q2 FY22 results · Jul–Sep 2021
Glenmark Pharmaceuticals reported revenue from operations of ₹3,147.45 crore (up 6.6% from Q2 FY21) and net profit of ₹274.81 crore (up 17.4% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,147.45 | 2,952.48 | +6.6% | 2,964.89 | +6.2% |
| Other income | (13.07) | (31.88) | Loss narrowed | 58.65 | Turned loss |
| Total income | 3,134.38 | 2,920.60 | +7.3% | 3,023.54 | +3.7% |
| Profit before tax | 384.96 | 339.38 | +13.4% | 443.55 | −13.2% |
| Net profit for the period | 274.81 | 233.99 | +17.4% | 306.53 | −10.3% |
| EPS, basic (₹) | 9.74 | 8.29 | +17.5% | 10.86 | −10.3% |
| Net margin (%) | 8.7 | 7.9 | 10.3 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,180.87 | 2,062.16 | +5.8% | 2,142.12 | +1.8% |
| Other income | 80.70 | 63.40 | +27.3% | 138.21 | −41.6% |
| Total income | 2,261.56 | 2,125.57 | +6.4% | 2,280.32 | −0.8% |
| Profit before tax | 877.61 | 461.55 | +90.1% | 598.40 | +46.7% |
| Net profit for the period | 754.26 | 402.88 | +87.2% | 489.42 | +54.1% |
| EPS, basic (₹) | 26.73 | 14.28 | +87.2% | 17.34 | +54.2% |
| Net margin (%) | 34.6 | 19.5 | 22.8 |
Consolidated
- Filed with BSE
- 13 Nov 2021, 17:22 IST
- Board meeting
- 12 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2021, 17:22 IST
- Board meeting
- 12 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE